Atyr Pharma Inc (ATYR) — 8-K Filings

8-K Filings (7)

• Atyr Pharma Faces Nasdaq Delisting Notice — Dec 5, 2025 Risk: high
  Atyr Pharma, Inc. announced on December 4, 2025, that it received a notice from the Nasdaq Stock Market indicating a failure to meet continued listing requireme
• aTYR PHARMA INC Files 8-K Report — Sep 15, 2025 Risk: low
  On September 15, 2025, aTYR PHARMA INC filed an 8-K report. The filing indicates "Other Events" and "Financial Statements and Exhibits" as key items. The compan
• Atyr Pharma Announces Board Changes and Shareholder Votes — May 6, 2025 Risk: medium
  Atyr Pharma, Inc. announced on May 1, 2025, a series of significant corporate actions. These include the departure of a director, the election of new directors,
• aTYR PHARMA INC Enters Material Definitive Agreement — Dec 23, 2024 Risk: medium
  On December 23, 2024, aTYR PHARMA INC entered into a Material Definitive Agreement. The filing also includes financial statements and exhibits related to this e
• aTYR PHARMA Director Departs, New Director Appointed — Dec 12, 2024 Risk: low
  On December 10, 2024, aTYR PHARMA, INC. reported the departure of Director Dr. Steven M. Altschuler and the appointment of Dr. David J. Earp as a new director.
• aTYR PHARMA Files 8-K Report — Jul 22, 2024 Risk: low
  On July 22, 2024, aTYR PHARMA, INC. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. The company is incorporated in D
• aTYR PHARMA Files 8-K: Director Changes, Officer Appointments — May 29, 2024 Risk: medium
  On May 22, 2024, aTYR PHARMA, INC. filed an 8-K report detailing several key events. These include the departure of a director, the election of new directors, a

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX